Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies

Journal of Neurochemistry

Volumn , Issue , 2016, Pages 54-70

  Mackenzie, Ian R A ^a   Neumann, Manuela ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

C9orf72; frontotemporal dementia; FUS; neuropathology; tau; TDP 43

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; DIPEPTIDE REPEAT PROTEIN; FUSED IN SARCOMA PROTEIN; PRION PROTEIN; PROGRANULIN; RNA BINDING PROTEIN EWS; TAR DNA BINDING PROTEIN; TATA BINDING PROTEIN ASSOCIATED FACTOR; TAU PROTEIN; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN;

ARGYROPHILIC GRAIN DISEASE; ATYPICAL FRONTOTEMPORAL LOBAR DEGENERATION WITH UBIQUITIN POSITIVE INCLUSION; AUTOPSY; BASOPHILIC INCLUSION BODY DISEASE; C9ORF72 GENE; CLINICAL FEATURE; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; FAMILIAL DISEASE; FRONTOTEMPORAL DEMENTIA; FRONTOTEMPORAL DEMENTIA AND PARKINSONISM LINKED TO CHROMOSOME 17 WITH TAU MUTATION; FRONTOTEMPORAL LOBAR DEGENERATION WITH FET POSITIVE INCLUSION; FRONTOTEMPORAL LOBAR DEGENERATION WITH INCLUSION POSITIVE FOR UBIQUITIN PROTEASOME SYSTEM MARKER; FRONTOTEMPORAL LOBAR DEGENERATION WITH TAU POSITIVE INCLUSION; FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP 43 POSITIVE INCLUSION TYPE A; FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP 43 POSITIVE INCLUSION TYPE B; FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP 43 POSITIVE INCLUSION TYPE C; FRONTOTEMPORAL LOBAR DEGENERATION WITH TDP 43 POSITIVE INCLUSION TYPE D; GENE; GENE MUTATION; GENETIC ASSOCIATION; GLOBULAR GLIAL TAUOPATHY; GRN GENE; HUMAN; MAPT GENE; MOLECULAR PATHOLOGY; NEUROLOGIC DISEASE; NEURONAL INTERMEDIATE FILAMENT INCLUSION DISEASE; NEUROPATHOLOGY; NONHUMAN; PICK PRESENILE DEMENTIA; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN DEFECT; PROTEIN FUNCTION; PROTEIN METABOLISM; REVIEW; TARDBP GENE; TAUOPATHY; VCP GENE;

EID: 84981266814     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13588     Document Type: Review

References (170)

1. Ahmed Z., Bigio E. H., Budka H. et al. (2013) Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathol. 126, 537–544.
2. Amador-Ortiz C., Lin W. L., Ahmed Z., Personett D., Davies P., Duara R., Graff-Radford N. R., Hutton M. L. and Dickson D. W. (2007) TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann. Neurol. 61, 435–445.
3. Arai T., Hasegawa M., Akiyama H. et al. (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602–611.
4. Arai T., Mackenzie I. R., Hasegawa M., Nonoka T., Niizato K., Tsuchiya K., Iritani S., Onaya M. and Akiyama H. (2009) Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol. 117, 125–136.
5. Ash P. E., Bieniek K. F., Gendron T. F. et al. (2013) Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 77, 639–646.
6. Baborie A., Griffiths T. D., Jaros E. et al. (2015) Accumulation of dipeptide repeat proteins predates that of TDP-43 in frontotemporal lobar degeneration associated with hexanucleotide repeat expansions in C9ORF72 gene. Neuropathol. Appl. Neurobiol. 41, 601–612.
7. Baker M., Mackenzie I. R., Pickering-Brown S. M. et al. (2006) Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 442, 916–919.
8. Benajiba L., Le Ber I., Camuzat A. et al. (2009) TARDBP mutations in motoneuron disease with frontotemporal lobar degeneration. Ann. Neurol. 65, 470–473.
9. Bieniek K. F., Murray M. E., Rutherford N. J. et al. (2013) Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion. Acta Neuropathol. 125, 289–302.
10. Bigio E. H., Brown D. F. and White C. L., 3rd (1999) Progressive supranuclear palsy with dementia: cortical pathology. J. Neuropathol. Exp. Neurol. 58, 359–364.
11. Bigio E. H., Wu J. Y., Deng H. X. et al. (2013) Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathol. 125, 463–465.
12. van Blitterswijk M., Baker M. C., DeJesus-Hernandez M. et al. (2013) C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology 81, 1332–1341.
13. Borroni B., Bonvicini C., Alberici A. et al. (2009) Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. Hum. Mutat. 30, E974–E983.
14. Borroni B., Archetti S., Del Bo R. et al. (2010) TARDBP mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course. Rejuvenation Res. 13, 509–517.
15. Braak H. and Braak E. (1989) Cortical and subcortical argyrophilic grains characterize a disease associated with adult onset dementia. Neuropathol. Appl. Neurobiol. 15, 13–26.
16. Braak H. and Braak E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239–259.
17. Braak H. and Braak E. (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18, 351–357.
18. Braak H. and Del Tredici K. (2011) Alzheimer's pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol. 121, 589–595.
19. Braak H., Thal D. R., Ghebremedhin E. and Del Tredici K. (2011) Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960–969.
20. Braak H., Brettschneider J., Ludolph A. C., Lee V. M., Trojanowski J. Q. and Del Tredici K. (2013) Amyotrophic lateral sclerosis–a model of corticofugal axonal spread. Nat. Rev. Neurol. 9, 708–714.
21. Brandmeir N. J., Geser F., Kwong L. K., Zimmerman E., Qian J., Lee V. M. and Trojanowski J. Q. (2008) Severe subcortical TDP-43 pathology in sporadic frontotemporal lobar degeneration with motor neuron disease. Acta Neuropathol. 115, 123–131.
22. Brelstaff J., Lashley T., Holton J. L., Lees A. J., Rossor M. N., Bandopadhyay R. and Revesz T. (2011) Transportin1: a marker of FTLD-FUS. Acta Neuropathol. 122, 591–600.
23. Brettschneider J., Del Tredici K., Toledo J. B. et al. (2013) Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann. Neurol. 74, 20–38.
24. Brettschneider J., Del Tredici K., Irwin D. J. et al. (2014) Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol. 127, 423–439.
25. Broustal O., Camuzat A., Guillot-Noel L. et al. (2010) FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis. J. Alzheimers Dis. 22, 765–769.
26. Buratti E. and Baralle F. E. (2010) The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol. 7, 420–429.
27. Cairns N. J., Grossman M., Arnold S. E. et al. (2004a) Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology 63, 1376–1384.
28. Cairns N. J., Zhukareva V., Uryu K. et al. (2004b) alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am. J. Pathol. 164, 2153–2161.
29. Cairns N. J., Bigio E. H., Mackenzie I. R. et al. (2007a) Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. (Berl) 114, 5–22.
30. Cairns N. J., Neumann M., Bigio E. H. et al. (2007b) TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am. J. Pathol. 171, 227–240.
31. de Calignon A., Polydoro M., Suarez-Calvet M. et al. (2012) Propagation of tau pathology in a model of early Alzheimer's disease. Neuron 73, 685–697.
32. Chew J., Gendron T. F., Prudencio M. et al. (2015) C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science 348, 1151–1154.
33. Clavaguera F., Hench J., Goedert M. and Tolnay M. (2015) Invited review: prion-like transmission and spreading of tau pathology. Neuropathol. Appl. Neurobiol. 41, 47–58.
34. Couthouis J., Hart M. P., Shorter J. et al. (2011) A yeast functional screen predicts new candidate ALS disease genes. Proc. Natl Acad. Sci. USA 108, 20881–20890.
35. Cruts M., Gijselinck I., van der Zee J. et al. (2006) Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature 442, 920–924.
36. Davidson Y. S., Barker H., Robinson A. C. et al. (2014) Brain distribution of dipeptide repeat proteins in frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol. Commun. 2, 70.
37. Davidson Y., Robinson A. C., Liu X. et al. (2015) Neurodegeneration in Frontotemporal Lobar Degeneration and Motor Neurone Disease associated with expansions in C9orf72 is linked to TDP-43 pathology and not associated with aggregated forms of dipeptide repeat proteins. Neuropathol. Appl. Neurobiol. 42, 242–254.
38. De Muynck L. and Van Damme P. (2011) Cellular effects of progranulin in health and disease. J. Mol. Neurosci. 45, 549–560.
39. DeJesus-Hernandez M., Mackenzie I. R., Boeve B. F. et al. (2011) Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 72, 245–256.
40. Deng H. X., Chen W., Hong S. T. et al. (2011) Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 477, 211–215.
41. Dickson D. W., Bergeron C., Chin S. S. et al. (2002) Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J. Neuropathol. Exp. Neurol. 61, 935–946.
42. Dormann D., Rodde R., Edbauer D. et al. (2010) ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO J. 29, 2841–2857.
43. Dormann D., Madl T., Valori C. F. et al. (2012) Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO J. 31, 4258–4275.
44. Edbauer D. and Haass C. (2015) An amyloid-like cascade hypothesis for C9orf72 ALS/FTD. Curr. Opin. Neurobiol. 36, 99–106.
45. Fahed A. C., McDonough B., Gouvion C. M. et al. (2014) UBQLN2 mutation causing heterogeneous X-linked dominant neurodegeneration. Ann. Neurol. 75, 793–798.
46. Fatima M., Tan R., Halliday G. M. and Kril J. J. (2015) Spread of pathology in amyotrophic lateral sclerosis: assessment of phosphorylated TDP-43 along axonal pathways. Acta Neuropathol. Commun. 3, 47.
47. Floris G., Borghero G., Cannas A. et al. (2015) Clinical phenotypes and radiological findings in frontotemporal dementia related to TARDBP mutations. J. Neurol. 262, 375–384.
48. Forman M. S., Farmer J., Johnson J. K. et al. (2006a) Frontotemporal dementia: clinicopathological correlations. Ann. Neurol. 59, 952–962.
49. Forman M. S., Mackenzie I. R., Cairns N. J. et al. (2006b) Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J. Neuropathol. Exp. Neurol. 65, 571–581.
50. Freeman S. H., Spires-Jones T., Hyman B. T., Growdon J. H. and Frosch M. P. (2008) TAR-DNA binding protein 43 in Pick disease. J. Neuropathol. Exp. Neurol. 67, 62–67.
51. Freischmidt A., Wieland T., Richter B. et al. (2015) Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 18, 631–636.
52. Gami P., Murray C., Schottlaender L. et al. (2015) A 30-unit hexanucleotide repeat expansion in C9orf72 induces pathological lesions with dipeptide-repeat proteins and RNA foci, but not TDP-43 inclusions and clinical disease. Acta Neuropathol. 130, 599–601.
53. Gendron T. F., Bieniek K. F., Zhang Y. J. et al. (2013) Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. Acta Neuropathol. 126, 829–844.
54. Gendron T. F., Belzil V. V., Zhang Y. J. and Petrucelli L. (2014) Mechanisms of toxicity in C9FTLD/ALS. Acta Neuropathol. 127, 359–376.
55. Gendron T. F., van Blitterswijk M., Bieniek K. F. et al. (2015) Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathol. 130, 559–573.
56. Geser F., Martinez-Lage M., Robinson J. et al. (2009) Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch. Neurol. 66, 180–189.
57. Ghetti B., Wszolek Z. K., Boeve B. F., Spina S. and Goedert M. (2011) Frontotemporal dementia and parkinsonism linked to chromosome 17, in Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, (Dickson D. W. and Weller R. O., eds.), pp. 110–134. Blackwell Publishing Ltd., Chichester, UK.
58. Gijselinck I., Van Langenhove T., van der Zee J. et al. (2012) A C9orf72 promoter repeat expansion in a Flanders-Belgian cohort with disorders of the frontotemporal lobar degeneration-amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet Neurol. 11, 54–65.
59. Gijselinck I., Van Mossevelde S., van der Zee J. et al. (2015) Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology 85, 2116–2125.
60. Gomez-Deza J., Lee Y. B., Troakes C., Nolan M., Al-Sarraj S., Gallo J. M. and Shaw C. E. (2015) Dipeptide repeat protein inclusions are rare in the spinal cord and almost absent from motor neurons in C9ORF72 mutant amyotrophic lateral sclerosis and are unlikely to cause their degeneration. Acta Neuropathol. Commun. 3, 38.
61. Guo J. L. and Lee V. M. (2014) Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med. 20, 130–138.
62. Hasegawa M., Arai T., Nonaka T. et al. (2008) Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann. Neurol. 64, 60–70.
63. Hasegawa M., Nonaka T., Tsuji H., Tamaoka A., Yamashita M., Kametani F., Yoshida M., Arai T. and Akiyama H. (2011) Molecular dissection of TDP-43 proteinopathies. J. Mol. Neurosci. 45, 480–485.
64. Hatanpaa K. J., Bigio E. H., Cairns N. J. et al. (2008) TAR DNA-Binding Protein 43 Immunohistochemistry Reveals Extensive Neuritic Pathology in FTLD-U: a Midwest-Southwest Consortium for FTLD Study. J. Neuropathol. Exp. Neurol. 67, 271–279.
65. Holm I. E., Englund E., Mackenzie I. R., Johannsen P. and Isaacs A. M. (2007) A Reassessment of the Neuropathology of Frontotemporal Dementia Linked to Chromosome 3. J. Neuropathol. Exp. Neurol. 66, 884–891.
66. Holm I. E., Isaacs A. M. and Mackenzie I. R. (2009) Absence of FUS-immunoreactive pathology in frontotemporal dementia linked to chromosome 3 (FTD-3) caused by mutation in the CHMP2B gene. Acta Neuropathol. 118, 719–720.
67. Hsiung G. Y., DeJesus-Hernandez M., Feldman H. H. et al. (2012) Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. Brain 135, 709–722.
68. Huey E. D., Ferrari R., Moreno J. H. et al. (2012) FUS and TDP43 genetic variability in FTD and CBS. Neurobiol. Aging 33, 1016, e1019–e1017.
69. Irwin D. J., Brettschneider J., McMillan C. T. et al. (2015) Deep clinical and neuropathological phenotyping of Pick's disease. Ann. Neurol. 79, 272–287.
70. Isaacs A. M., Johannsen P., Holm I., Nielsen J. E. and consortium F. R. (2011) Frontotemporal dementia caused by CHMP2B mutations. Curr. Alzheimer Res., 8, 246–251.
71. Ishihara K., Araki S., Ihori N., Shiota J., Kawamura M., Yoshida M., Hashizume Y. and Nakano I. (2005) Argyrophilic grain disease presenting with frontotemporal dementia: a neuropsychological and pathological study of an autopsied case with presenile onset. Neuropathology 25, 165–170.
72. Johnson J. K., Head E., Kim R., Starr A. and Cotman C. W. (1999) Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch. Neurol. 56, 1233–1239.
73. Josephs K. A., Stroh A., Dugger B. and Dickson D. W. (2009) Evaluation of subcortical pathology and clinical correlations in FTLD-U subtypes. Acta Neuropathol. 118, 349–358.
74. Josephs K. A., Murray M. E., Whitwell J. L., Parisi J. E., Petrucelli L., Jack C. R., Petersen R. C. and Dickson D. W. (2014a) Staging TDP-43 pathology in Alzheimer's disease. Acta Neuropathol. 127, 441–450.
75. Josephs K. A., Whitwell J. L., Weigand S. D. et al. (2014b) TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol. 127, 811–824.
76. Kabashi E., Valdmanis P. N., Dion P. et al. (2008) TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat. Genet. 40, 572–574.
77. Kassubek J., Muller H. P., Del Tredici K., Brettschneider J., Pinkhardt E. H., Lule D., Bohm S., Braak H. and Ludolph A. C. (2014) Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain 137, 1733–1740.
78. Keage H. A., Hunter S., Matthews F. E., Ince P. G., Hodges J., Hokkanen S. R., Highley J. R., Dening T. and Brayne C. (2014) TDP-43 pathology in the population: prevalence and associations with dementia and age. J. Alzheimers Dis. 42, 641–650.
79. Kertesz A., McMonagle P., Blair M., Davidson W. and Munoz D. G. (2005) The evolution and pathology of frontotemporal dementia. Brain 128, 1996–2005.
80. Kimonis V. E., Fulchiero E., Vesa J. and Watts G. (2008) VCP disease associated with myopathy, Paget disease of bone and frontotemporal dementia: review of a unique disorder. Biochim. Biophys. Acta 1782, 744–748.
81. Kovacs G. G., Murrell J. R., Horvath S., Haraszti L., Majtenyi K., Molnar M. J., Budka H., Ghetti B. and Spina S. (2009) TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Mov. Disord. 24, 1843–1847.
82. Kovacs G. G., Rozemuller A. J., van Swieten J. C. et al. (2013) Neuropathology of the hippocampus in FTLD-Tau with Pick bodies: a study of the BrainNet Europe Consortium. Neuropathol. Appl. Neurobiol. 39, 166–178.
83. Kovacs G. G., Ferrer I., Grinberg L. T. et al. (2015a) Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathol. 131, 87–102.
84. Kovacs G. G., dervan Zee J., Hort J., Kristoferitsch W., Leitha T., Hoftberger R., Strobel T., Van Broeckhoven C. and Matej R. (2015b) Clinicopathological description of two cases with SQSTM1 gene mutation associated with frontotemporal dementia. Neuropathology 36, 27–38.
85. Kwiatkowski T. J., Jr, Bosco D. A., Leclerc A. L. et al. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205–1208.
86. Lagier-Tourenne C., Polymenidou M., Hutt K. R. et al. (2012) Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat. Neurosci. 15, 1488–1497.
87. Lashley T., Rohrer J. D., Bandopadhyay R. et al. (2011) A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 134, 2548–2564.
88. Lashley T., Rohrer J. D., Mahoney C., Gordon E., Beck J., Mead S., Warren J., Rossor M. and Revesz T. (2014) A pathogenic progranulin mutation and C9orf72 repeat expansion in a family with frontotemporal dementia. Neuropathol. Appl. Neurobiol. 40, 502–513.
89. Lee G. and Leugers C. J. (2012) Tau and tauopathies. Prog. Mol. Biol. Transl. Sci. 107, 263–293.
90. Lee V. M., Goedert M. and Trojanowski J. Q. (2001) Neurodegenerative tauopathies. Ann. Rev. Neurosci. 24, 1121–1159.
91. Lee Y. B., Chen H. J., Peres J. N. et al. (2013) Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 5, 1178–1186.
92. Lewis J. and Dickson D. W. (2015) Propagation of tau pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol. 131, 27–48.
93. Liu L., Drouet V., Wu J. W., Witter M. P., Small S. A., Clelland C. and Duff K. (2012) Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7, e31302.
94. Lomen-Hoerth C., Anderson T. and Miller B. (2002) The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 59, 1077–1079.
95. Mackenzie I. R. (2007) The neuropathology and clinical phenotype of FTD with progranulin mutations. Acta Neuropathol. 114, 49–54.
96. Mackenzie I. R., Baborie A., Pickering-Brown S., Plessis D. D., Jaros E., Perry R. H., Neary D., Snowden J. S. and Mann D. M. (2006) Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol. 112, 539–549.
97. Mackenzie I. R., Foti D., Woulfe J. and Hurwitz T. A. (2008) Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain 131, 1282–1293.
98. Mackenzie I. R., Neumann M., Bigio E. H. et al. (2009) Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathol. 117, 15–18.
99. Mackenzie I. R., Neumann M., Bigio E. H. et al. (2010) Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 119, 1–4.
100. Mackenzie I. R., Munoz D. G., Kusaka H., Yokota O., Ishihara K., Roeber S., Kretzschmar H. A., Cairns N. J. and Neumann M. (2011a) Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol. 121, 207–218.
101. Mackenzie I. R., Neumann M., Baborie A. et al. (2011b) A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 122, 111–113.
102. Mackenzie I. R., Arzberger T., Kremmer E. et al. (2013) Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathol. 126, 859–879.
103. Mackenzie I. R., Frick P., Grasser F. A. et al. (2015) Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathol. 130, 845–861.
104. Maniecka Z. and Polymenidou M. (2015) From nucleation to widespread propagation: a prion-like concept for ALS. Virus Res. 207, 94–105.
105. Mann D. M., Rollinson S., Robinson A. et al. (2013) Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol. Commun. 1, 68.
106. McKhann G. M., Albert M. S., Grossman M., Miller B., Dickson D. and Trojanowski J. Q. (2001) Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch. Neurol. 58, 1803–1809.
107. Mesulam M., Wicklund A., Johnson N., Rogalski E., Leger G. C., Rademaker A., Weintraub S. and Bigio E. H. (2008) Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann. Neurol. 63, 709–719.
108. Mizielinska S. and Isaacs A. M. (2014) C9orf72 amyotrophic lateral sclerosis and frontotemporal dementia: gain or loss of function? Curr. Opin. Neurol. 27, 515–523.
109. Mizielinska S., Lashley T., Norona F. E., Clayton E. L., Ridler C. E., Fratta P. and Isaacs A. M. (2013) C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. 126, 845–857.
110. Mori K., Arzberger T., Grasser F. A. et al. (2013a) Bidirectional transcripts of the expanded C9orf72 hexanucleotide repeat are translated into aggregating dipeptide repeat proteins. Acta Neuropathol. 126, 881–893.
111. Mori K., Weng S. M., Arzberger T. et al. (2013b) The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335–1338.
112. Munoz D. G., Neumann M., Kusaka H., Yokota O., Ishihara K., Terada S., Kuroda S. and Mackenzie I. R. (2009) FUS pathology in basophilic inclusion body disease. Acta Neuropathol. 118, 617–627.
113. Murray M. E., Dejesus-Hernandez M., Rutherford N. J. et al. (2011) Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathol. 122, 673–690.
114. Neary D., Snowden J. S., Gustafson L. et al. (1998) Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51, 1546–1554.
115. Neumann M., Sampathu D. M., Kwong L. K. et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133.
116. Neumann M., Kwong L. K., Truax A. C. et al. (2007) TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J. Neuropathol. Exp. Neurol. 66, 177–183.
117. Neumann M., Kwong L. K., Lee E. B. et al. (2009a) Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 117, 137–149.
118. Neumann M., Rademakers R., Roeber S., Baker M., Kretzschmar H. A. and Mackenzie I. R. (2009b) A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain 132, 2922–2931.
119. Neumann M., Roeber S., Kretzschmar H. A., Rademakers R., Baker M. and Mackenzie I. R. (2009c) Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol. 118, 605–616.
120. Neumann M., Bentmann E., Dormann D. et al. (2011) FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain 134, 2595–2609.
121. Neumann M., Valori C. F., Ansorge O. et al. (2012) Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations. Acta Neuropathol. 124, 705–716.
122. O'Rourke J. G., Bogdanik L., Muhammad A. K. et al. (2015) C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron 88, 892–901.
123. Padovani A., Agosti C., Premi E., Bellelli G. and Borroni B. (2007) Extrapyramidal symptoms in Frontotemporal Dementia: prevalence and clinical correlations. Neurosci. Lett. 422, 39–42.
124. Paloneva J., Kestila M., Wu J. et al. (2000) Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia with bone cysts. Nat. Genet. 25, 357–361.
125. Paloneva J., Manninen T., Christman G. et al. (2002) Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am. J. Hum. Genet. 71, 656–662.
126. Peters O. M., Cabrera G. T., Tran H. et al. (2015) Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron 88, 902–909.
127. Piguet O., Halliday G. M., Reid W. G., Casey B., Carman R., Huang Y., Xuereb J. H., Hodges J. R. and Kril J. J. (2011) Clinical phenotypes in autopsy-confirmed Pick disease. Neurology 76, 253–259.
128. Polymenidou M., Lagier-Tourenne C., Hutt K. R. et al. (2011) Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 14, 459–468.
129. Pottier C., Bieniek K. F., Finch N. et al. (2015) Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol. 130, 77–92.
130. Proudfoot M., Gutowski N. J., Edbauer D., Hilton D. A., Stephens M., Rankin J. and Mackenzie I. R. (2014) Early dipeptide repeat pathology in a frontotemporal dementia kindred with C9ORF72 mutation and intellectual disability. Acta Neuropathol. 127, 451–458.
131. Rademakers R., Baker M., Nicholson A. M. et al. (2012a) Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nat. Genet. 44, 200–205.
132. Rademakers R., Neumann M. and Mackenzie I. R. (2012b) Advances in understanding the molecular basis of frontotemporal dementia. Nat. Rev. Neurol. 8, 423–434.
133. Ravenscroft T. A., Baker M. C., Rutherford N. J. et al. (2013) Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS. Neurobiol. Aging 34, 2235, e2211–e2233.
134. Renton A. E., Majounie E., Waite A. et al. (2011) A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257–268.
135. Robinson J. L., Geser F., Stieber A., Umoh M., Kwong L. K., Van Deerlin V. M., Lee V. M. and Trojanowski J. Q. (2013) TDP-43 skeins show properties of amyloid in a subset of ALS cases. Acta Neuropathol. 125, 121–131.
136. Robinson A. C., Thompson J. C., Weedon L., Rollinson S., Pickering-Brown S., Snowden J. S., Davidson Y. S. and Mann D. M. (2014) No interaction between tau and TDP-43 pathologies in either frontotemporal lobar degeneration or motor neurone disease. Neuropathol. Appl. Neurobiol. 40, 844–854.
137. Roeber S., Mackenzie I. R., Kretzschmar H. A. and Neumann M. (2008) TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol. 116, 147–157.
138. Sama R. R., Ward C. L. and Bosco D. A. (2014) Functions of FUS/TLS from DNA repair to stress response: implications for ALS. ASN Neuro., 6, pii: 1759091414544472.
139. Sampathu D. M., Neumann M., Kwong L. K. et al. (2006) Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am. J. Pathol. 169, 1343–1352.
140. Schludi M. H., May S., Grasser F. A. et al. (2015) Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathol. 130, 537–555.
141. Sephton C. F., Cenik C., Kucukural A. et al. (2011) Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J. Biol. Chem. 286, 1204–1215.
142. Sha S., Hou C., Viskontas I. V. and Miller B. L. (2006) Are frontotemporal lobar degeneration, progressive supranuclear palsy and corticobasal degeneration distinct diseases? Nat. Clin. Pract. Neurol. 2, 658–665.
143. Skibinski G., Parkinson N. J., Brown J. M. et al. (2005) Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nat. Genet. 37, 806–808.
144. Smethurst P., Sidle K. C. and Hardy J. (2015) Review: prion-like mechanisms of transactive response DNA binding protein of 43 kDa (TDP-43) in amyotrophic lateral sclerosis (ALS). Neuropathol. Appl. Neurobiol. 41, 578–597.
145. Sreedharan J., Blair I. P., Tripathi V. B. et al. (2008) TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668–1672.
146. Stewart H., Rutherford N. J., Briemberg H., Krieger C., Cashman N., Fabros M., Baker M., Fok A., DeJesus-Hernandez M., Eisen A., Rademakers R. and Mackenzie I. R. A. (2012) Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol. 123, 409–417.
147. Synofzik M., Born C., Rominger A. et al. (2014) Targeted high-throughput sequencing identifies a TARDBP mutation as a cause of early-onset FTD without motor neuron disease. Neurobiol. Aging 35, 1212, e1211–e1215.
148. Tan A. Y. and Manley J. L. (2009) The TET family of proteins: functions and roles in disease. J. Mol. Cell. Biol. 1, 82–92.
149. Taylor K. I., Probst A., Miserez A. R., Monsch A. U. and Tolnay M. (2008) Clinical course of neuropathologically confirmed frontal-variant Alzheimer's disease. Nat. Clin. Pract. Neurol. 4, 226–232.
150. Ticozzi N., Vance C., Leclerc A. L. et al. (2011) Mutational analysis reveals the FUS homolog TAF15 as a candidate gene for familial amyotrophic lateral sclerosis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156, 285–290.
151. Tollervey J. R., Curk T., Rogelj B. et al. (2011) Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat. Neurosci. 14, 452–458.
152. Tolnay M. and Probst A. (2008) Argyrophilic grain disease. Handb. Clin. Neurol. 89, 553–563.
153. Tsuchiya K., Mitani K., Arai T., Yamada S., Komiya T., Esaki Y., Haga C., Yamanouchi H. and Ikeda K. (2001) Argyrophilic grain disease mimicking temporal Pick's disease: a clinical, radiological, and pathological study of an autopsy case with a clinical course of 15 years. Acta Neuropathol. 102, 195–199.
154. Tsuji H., Arai T., Kametani F. et al. (2012) Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain 135, 3380–3391.
155. Uchino A., Takao M., Hatsuta H. et al. (2015) Incidence and extent of TDP-43 accumulation in aging human brain. Acta Neuropathol. Commun. 3, 35.
156. Urwin H., Josephs K. A., Rohrer J. D. et al. (2010) FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol. 120, 33–41.
157. Uryu K., Nakashima-Yasuda H., Forman M. S. et al. (2008) Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J. Neuropathol. Exp. Neurol. 67, 555–564.
158. Van Deerlin V. M., Leverenz J. B., Bekris L. M. et al. (2008) TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 7, 409–416.
159. Van Langenhove T., van der Zee J., Sleegers K. et al. (2010) Genetic contribution of FUS to frontotemporal lobar degeneration. Neurology 74, 366–371.
160. Van Mossevelde S., der van Zee J., Gijselinck I. et al. (2016) Clinical features of TBK1 carriers compared with C9orf72, GRN and non-mutation carriers in a Belgian cohort. Brain 139, 452–467.
161. Vance C., Rogelj B., Hortobagyi T. et al. (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208–1211.
162. Walker L. C. and Jucker M. (2015) Neurodegenerative diseases: expanding the prion concept. Annu. Rev. Neurosci. 38, 87–103.
163. Wider C., Van Gerpen J. A., DeArmond S., Shuster E. A., Dickson D. W. and Wszolek Z. K. (2009) Leukoencephalopathy with spheroids (HDLS) and pigmentary leukodystrophy (POLD): a single entity? Neurology 72, 1953–1959.
164. Wilson R. S., Yu L., Trojanowski J. Q., Chen E. Y., Boyle P. A., Bennett D. A. and Schneider J. A. (2013) TDP-43 pathology, cognitive decline, and dementia in old age. JAMA Neurol. 70, 1418–1424.
165. Wong T. H., Chiu W. Z., Breedveld G. J. et al. (2014) PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology. Brain 137, 1361–1373.
166. Yan J., Deng H. X., Siddique N. et al. (2010) Frameshift and novel mutations in FUS in familial amyotrophic lateral sclerosis and ALS/dementia. Neurology 75, 807–814.
167. Yokota O., Davidson Y., Bigio E. H. et al. (2010) Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol. 120, 55–66.
168. Zhukareva V., Mann D., Pickering-Brown S. et al. (2002) Sporadic Pick's disease: a tauopathy characterized by a spectrum of pathological tau isoforms in gray and white matter. Ann. Neurol. 51, 730–739.
169. Zimprich A., Biskup S., Leitner P. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601–607.
170. Zu T., Liu Y., Banez-Coronel M. et al. (2013) RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl Acad. Sci. USA 110, E4968–E4977.